Letters to the Editor

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY
Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY
Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA
AstraZeneca, South San Francisco, CA
Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA; Center for Cell Clearance and the Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA
Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Haematologica Early view Feb 17, 2022 https://doi.org/10.3324/haematol.2021.279560